JP2013525414A5 - - Google Patents

Download PDF

Info

Publication number
JP2013525414A5
JP2013525414A5 JP2013506735A JP2013506735A JP2013525414A5 JP 2013525414 A5 JP2013525414 A5 JP 2013525414A5 JP 2013506735 A JP2013506735 A JP 2013506735A JP 2013506735 A JP2013506735 A JP 2013506735A JP 2013525414 A5 JP2013525414 A5 JP 2013525414A5
Authority
JP
Japan
Prior art keywords
group
pharmaceutical composition
composition according
bond
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013506735A
Other languages
English (en)
Japanese (ja)
Other versions
JP5870088B2 (ja
JP2013525414A (ja
Filing date
Publication date
Priority claimed from GBGB1007357.5A external-priority patent/GB201007357D0/en
Application filed filed Critical
Publication of JP2013525414A publication Critical patent/JP2013525414A/ja
Publication of JP2013525414A5 publication Critical patent/JP2013525414A5/ja
Application granted granted Critical
Publication of JP5870088B2 publication Critical patent/JP5870088B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013506735A 2010-04-30 2011-04-28 共役血液凝固第viii因子 Expired - Fee Related JP5870088B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1007357.5A GB201007357D0 (en) 2010-04-30 2010-04-30 Conjugated factor VIII
GB1007357.5 2010-04-30
PCT/GB2011/000662 WO2011135307A1 (en) 2010-04-30 2011-04-28 Conjugated blood coagulation factor viii

Publications (3)

Publication Number Publication Date
JP2013525414A JP2013525414A (ja) 2013-06-20
JP2013525414A5 true JP2013525414A5 (https=) 2014-06-19
JP5870088B2 JP5870088B2 (ja) 2016-02-24

Family

ID=42289987

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013506735A Expired - Fee Related JP5870088B2 (ja) 2010-04-30 2011-04-28 共役血液凝固第viii因子

Country Status (26)

Country Link
US (1) US20130150302A1 (https=)
EP (1) EP2563402A1 (https=)
JP (1) JP5870088B2 (https=)
KR (1) KR20130055619A (https=)
CN (1) CN102939108A (https=)
AP (1) AP2012006575A0 (https=)
AU (1) AU2011247147B2 (https=)
BR (1) BR112012027590A2 (https=)
CA (1) CA2797058A1 (https=)
CL (1) CL2012003039A1 (https=)
CO (1) CO6660443A2 (https=)
CR (1) CR20120579A (https=)
EA (1) EA201290938A1 (https=)
EC (1) ECSP12012314A (https=)
GB (2) GB201007357D0 (https=)
IL (1) IL222566A (https=)
MX (1) MX2012012683A (https=)
MY (1) MY160922A (https=)
NI (1) NI201200160A (https=)
NZ (1) NZ603939A (https=)
PE (1) PE20130254A1 (https=)
PH (1) PH12012502150A1 (https=)
RU (1) RU2012144555A (https=)
SG (1) SG184906A1 (https=)
WO (1) WO2011135307A1 (https=)
ZA (1) ZA201208989B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
ES2597954T3 (es) 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
MY190257A (en) 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
MX2020012103A (es) 2018-05-18 2021-01-29 Zhengzhou Gensciences Inc Proteina de fusion fviii mejorada y uso de la misma.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0407882B1 (pt) * 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
PT2363414T (pt) * 2004-11-12 2022-08-04 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
CN101163506B (zh) * 2004-12-27 2012-09-26 巴克斯特国际公司 聚合物-von Willebrand因子偶联物
AU2007245190B2 (en) * 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
CN101820920B (zh) 2007-10-09 2014-08-06 宝力泰锐克斯有限公司 新的缀合蛋白质和肽
DK2280734T3 (da) * 2008-04-24 2014-05-26 Cantab Biopharmaceuticals Patents Ltd Faktor-ix-konjugater med forlængede halveringstider
AU2009275358C1 (en) * 2008-07-21 2015-09-24 Polytherics Limited Novel reagents and method for conjugating biological molecules
GB0912485D0 (en) * 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method

Similar Documents

Publication Publication Date Title
JP2013525414A5 (https=)
CA2797058A1 (en) Conjugated blood coagulation factor viii
CA2796870A1 (en) Conjugated blood coagulation factor viia
JP2011519833A5 (https=)
RU2010147813A (ru) Конъюгаты фактора ix с увеличенным временем полужизни
JP7646888B2 (ja) 制御放出pth化合物の投薬レジメン
JP7483776B2 (ja) 放出制御pth化合物の漸増用量設定
Ding et al. Weak bond-based injectable and stimuli responsive hydrogels for biomedical applications
US8987230B2 (en) Hybrid gel comprising chemically crosslinked hyaluronic acid derivative and pharmaceutical composition comprising the same
JP7490563B2 (ja) Il-2コンジュゲート
JP4272537B2 (ja) Y型分鎖親水性ポリマー誘導体、それらの調製方法、前記誘導体および薬剤分子の結合生成物、ならびに前記結合生成物を含む医薬組成物
JP2008542285A5 (https=)
EA023208B1 (ru) Фармацевтические композиции, которые содержат имидазохинолин(амины) и их производные, пригодные для местного введения
JP2013522239A5 (https=)
ES2259914B1 (es) Nanoparticulas de quitosano y polietilenglicol como sistema de administracion de moleculas biologicamente activas.
JP2014040441A5 (https=)
JP6790133B2 (ja) マルチアームポリエチレングリコール及びその活性誘導体
ES2819217T3 (es) Conjugados de polímeros iónicos dipolares y factor VIII
TW200936168A (en) Compositions for sustained release delivery of proteins or peptides
JP6004449B2 (ja) トリブロックコポリマー及びその使用
JP2013520986A5 (https=)
TWI861015B (zh) 包含抗原肽-佐劑核苷酸結合物之免疫誘導劑及包含其之醫藥組成物
JP2011507913A5 (https=)
US20160272762A1 (en) Stearic acid derivatives and oleic acid derivatives of multi-arm polyethylene glycol
JP2012516347A5 (https=)